BBIO Stock Analysis

BridgeBio Pharma Inc
HEALTHCARE BIOTECHNOLOGY

Back to Winners View Yahoo Finance Chart
Buy on the Dip
Strong Caution Mixed Weak Unavailable
StockValueFinder Grade
F
30.04 / 100
Weak
Confidence: High (80.0%) Coverage: 80.0%
Business Quality 5.5
Financial Strength 43.0
Earnings & Growth 50.5
Valuation 9.3
Market Strength 54.1
The grade combines Business Quality, Financial Strength, Earnings & Growth, Valuation, and Market Strength. Rating and Trend remain separate signals.
Rating AVOID
Avoid
The screening rules are warning against this setup.
Rating is the simple decision label from the screening rules.
Trend SELL / AVOID TREND
Weak Trend
The current trend is unfavorable.
Trend shows whether price action is helping or hurting the setup.
P/E Ratio -19.06
Not Meaningful
Negative or missing earnings make P/E hard to use.
P/E shows how much investors pay for each dollar of earnings.
ROIC -111.83%
Poor
Negative ROIC suggests capital is not being used profitably.
ROIC measures how efficiently capital turns into profit.
Debt Payback -4.14 yrs
Unavailable
Debt payback is unavailable or not meaningful.
Debt payback estimates how quickly debt could be covered.
Interest Coverage -10.72x
Poor
Negative coverage means earnings are not covering interest costs.
Interest coverage shows how easily earnings cover interest costs.
Price $68.56
Market Price
Price alone is not a buy or sell signal.
Price should be judged with valuation, quality, and trend.
Last updated: 2026-10-25 20:00:47

Performance Overview

Trailing adjusted-close returns as of 2026-06-26. Benchmark is SPY.

YTD Return

BBIO -8.17%
SPY +7.47%

1-Year Return

BBIO +55.67%
SPY +20.46%

3-Year Return

BBIO +353.45%
SPY +75.39%

5-Year Return

BBIO +16.20%
SPY +82.87%

Returns are calculated from adjusted close prices and may differ from broker or research-site totals depending on data source, dividend handling, benchmark choice, and latest available trading date.

Legacy Screening Checks

This page uses cached SQL data from the latest StockValueFinder scan, so it loads fast without hitting Alpha Vantage on every page view.

37%
EPS Strength
FAIL

Looks for positive and improving earnings per share.

ROIC 10%+
FAIL

Looks for strong return on invested capital.

Interest Coverage 6+
FAIL

Checks whether operating income comfortably covers interest expense.

Debt Payback ≤ 3 Years
PASS

Checks whether free cash flow could pay down long-term debt quickly.

P/E 15 or Less
PASS

Checks whether valuation is reasonable under the current rule set.

Moving Average Trend
SELL / AVOID TREND

Uses 20-day, 50-day, and 200-day moving averages for entry timing context.

A high StockValueFinder score is a research signal, not a guarantee. Strong companies can still fall during recessions, sector downturns, valuation resets, or company-specific events. Always review the business, risks, SEC filings, valuation, and your personal investment goals before buying.

Cached Technical Data

Moving average values from the latest stored scan.

20-Day MA66.50
50-Day MA71.38
200-Day MA72.90
MA Score1

Latest Published Stock Research

Research generated: October 24, 2026

BBIO Stock Analysis: Why BridgeBio Pharma Inc Scored 37% in Stock Value Finder

BridgeBio Pharma Inc (BBIO): An Educational StockValueFinder Review

BridgeBio Pharma Inc is a biotechnology company focused on genetic diseases. This in-depth analysis will review the latest metrics provided by StockValueFinder to help investors understand the current state of BBIO's financial health and valuation.

Why the StockValueFinder Score Matters StockValueFinder evaluates companies based on various fundamental and technical indicators, providing an overall score that ranges from 0% to 100%. A score of 37% for BridgeBio Pharma Inc suggests that the company has significant room for improvement in several key financial metrics. The rating given is "AVOID," indicating that StockValueFinder does not recommend investing in BBIO at this time.

EPS Strength and Consistency Earnings Per Share (EPS) measures a company's profitability on a per-share basis, reflecting how much profit a company generates relative to its number of shares outstanding. A consistent positive trend in EPS is crucial for long-term investment success.

**StockValueFinder Result:** Did not pass

Since detailed historical EPS data was not provided, we cannot assess the exact figures, but the failure indicates that BBIO's earnings performance may be inconsistent or negative over recent periods.

ROIC and Capital Efficiency Return on Invested Capital (ROIC) is a critical metric for understanding how effectively a company uses its capital to generate profits. A higher ROIC suggests better use of resources compared to lower rates.

**StockValueFinder Result:** -111.83%

**Strong Range:** 10% or higher - **Weak Range:** Below 5% - **Why It Failed:** BBIO's ROIC is significantly negative, indicating poor capital efficiency and potentially high costs relative to its earnings. - **Example for Context:** A company with a 15% ROIC uses its capital more efficiently than one with only 4%, translating into better long-term growth prospects.

Interest Coverage and Financial Safety Interest coverage ratio measures a company's ability to pay the interest on outstanding debt. This is crucial in assessing financial stability, especially during economic downturns or periods of high-interest rates.

**StockValueFinder Result:** Did not pass

**Strong Range:** 6x or higher - **Weak Range:** Below 2x - **Why It Failed:** Without specific numbers, the failure suggests that BBIO's interest coverage is likely low, indicating potential financial strain if debt levels rise. - **Example for Context:** A company with an 8x interest coverage ratio can better manage its debt payments compared to a company with only 2x coverage.

Debt Payback and Balance Sheet Discipline Debt payback period measures how long it would take a company to repay all of its outstanding debt using current earnings before interest, taxes, depreciation, and amortization (EBITDA).

**StockValueFinder Result:** -4.14 years

**Strong Range:** 3 years or less - **Weak Range:** More than 7 years - **Why It Passed:** Although the negative value is unusual and suggests a company with significant operating losses relative to debt, it technically meets StockValueFinder's criteria for passing due to being within the specified range. - **Example for Context:** A company that can repay its debts in 1.5 years is more financially disciplined than one needing 7 years.

P/E Ratio and Valuation Discipline The Price-to-Earnings (P/E) ratio compares a stock’s market price with its earnings per share, helping investors gauge whether the stock is overvalued or undervalued relative to its peers.

**StockValueFinder Result:** -19.06

**Strong Range:** 15 or lower - **Weak Range:** Above 40 - **Why It Passed:** Despite being negative, which typically indicates a loss situation (no earnings), the ratio is considered within an acceptable range for valuation discipline. - **Example for Context:** A P/E of 8 may indicate better value than a P/E of 40 if the company's business quality remains strong.

Moving Average Trend and Entry Timing Moving averages are technical indicators used to identify trends in stock prices. They help investors make informed decisions about entry points based on historical price patterns rather than as proof that the stock must rise.

**StockValueFinder Result:** SELL / AVOID TREND

**Sell Signal:** Indicates a downward trend. - **Why It Fails Entry Timing Discipline:** The signal suggests BBIO is in a sell or avoid phase, indicating poor timing for entry based on current trends.

Overall Financial Strengths and Weaknesses **Strengths:** - Passed debt payback test, suggesting the company can manage its debts effectively within StockValueFinder's criteria. - Passed P/E valuation discipline despite negative earnings, implying relative value in terms of price-to-earnings ratio.

**Weaknesses:** - Failed EPS consistency and ROIC tests, indicating poor profitability trends and capital efficiency. - Failed interest coverage test, suggesting potential financial strain from debt obligations. - Moving average trend signals a sell or avoid phase, discouraging entry based on current market conditions.

Risks and Limitations Investing in biotechnology companies like BridgeBio Pharma Inc involves significant risks due to the high costs of drug development and regulatory hurdles. Negative EPS trends, poor ROIC, low interest coverage ratios, and unfavorable moving average signals all contribute to a higher risk profile for BBIO.

Additionally, the lack of detailed historical data limits our ability to conduct a comprehensive analysis based solely on the provided metrics. Investors should consider additional research and consult with financial advisors before making investment decisions.

Educational Conclusion This article has reviewed BridgeBio Pharma Inc's performance across various financial metrics using StockValueFinder’s criteria. The overall score of 37% and "AVOID" rating indicate that BBIO currently faces significant challenges in terms of profitability, capital efficiency, and market trends.

Understanding these metrics is crucial for identifying high-quality stocks with strong fundamentals. By analyzing EPS consistency, ROIC, interest coverage, debt payback, P/E ratios, and moving averages, investors can make more informed decisions about the long-term potential of their investments.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings

Research Attribution
Max Qwen II

Specializing in monetary economics, market incentives, and investment risk.

AI-assisted research generated October 24, 2026

30-Day Trendline Analysis

Optional intraday chart with rising support, falling resistance, and multi-timeframe views.

Load detailed price structure only when needed. Downloads roughly 30 days of 5-minute candles, identifies swing points, then calculates validated support and resistance lines.
Scroll to Top